Clinical trial interest from patients with COPD approached after Lung Cancer Screening

<bold>Introduction:</bold> Recruitment to COPD clinical trials can be challenging and those known to secondary care often fail screening. Risk factors for COPD and lung cancer overlap. Lung Cancer Screening (LCS) offers the opportunity for participants to take part in clinical trials. We report our experience approaching people after LCS to offer participation in a COPD clinical trial. <bold>Methods:</bold> Invitation letters were posted to SUMMIT LCS study participants with known COPD. Participants were asked to register interest for potential recruitment to an industry-sponsored COPD interventional trial by phone or email. A telephone pre-screening questionnaire was then conducted to assess eligibility prior to sending further trial information. Individuals who were ineligible for this specific study at pre-screening were asked if they were interested in being contacted about other research. <bold>Results:</bold> 200 LCS participants were contacted between 2nd August and 10th November 2023. 37 (18.5%) participants contacted the trial team to register interest in taking part in the study. 36/37 (97%) completed an initial pre-screener, of which 69% (n=25/36) were eligible. All 11 participants who were ineligible for this study were happy to be contacted about other research. <bold>Conclusions:</bold> 18.5% of LCS participants invited to an interventional study in COPD expressed interest in taking part. Those who responded were also interested in other research, creating a pool of research participants. LCS is being implemented across many settings and our experience suggests that this method of COPD trial recruitment is an important new route to widening trial participation. We recommend that LCS programmes include consent to contact for research.